HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 577-588 of 4,505
Drug study icon
Not Yet RecruitingNCT07585383

A Phase I study Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

Official study title

A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single and Multiple Doses of KR23248 Capsules in Healthy Adult Subjects

This study isn't recruiting yet.

Location not clearly listed
SchizophreniaMedication studyAges 18–45
Countries
Sponsor
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Other study type icon
Not Yet RecruitingNCT06695676

Effects of Lurasidone on Left Ventricle Systolic Functions

Official study title

Evaluation of Left Ventricle Systolic Functions of Patients On Lurasidone

This study isn't recruiting yet.

In Aydin
Schizophrenia, BipolarityObservational studyAges 18–65
Countries
Türkiye
Sponsor
Aydin Adnan Menderes University
Behavioral study icon
Not Yet RecruitingNCT07555275

Testing a Peer-Support Group for Veterans Who Hear Voices

Official study title

A Multisited Efficacy Trial of Veteran Voices and Visions

This study isn't recruiting yet.

Multiple locations, including West Los Angeles
SchizophreniaBehavioural studyAges 18+
Countries
United States
Sponsor
VA Office of Research and Development (Government agency)
Drug study icon
CompletedNCT00095524

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Official study title

A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States, United Kingdom, Brazil
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.